GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common Stock
13. April 2023 09:22 ET
|
GlucoTrack, Inc.
Rutherford, NJ, April 13, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and...
GlucoTrack Announces Proposed Underwritten Public Offering of Common Stock
12. April 2023 17:50 ET
|
GlucoTrack, Inc.
Rutherford, NJ, April 12, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and...
GLUCOTRACK PROVIDES SHAREHOLDER UPDATE
14. März 2023 10:00 ET
|
GlucoTrack, Inc.
Rutherford, NJ, March 14, 2023 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a medical device and digital health platform company focused on diabetes and...
GLUCOTRACK GIBT DIE EINSTELLUNG VON DR. MARK TAPSAK BEKANNT
15. Oktober 2022 09:24 ET
|
GlucoTrack, Inc.
Rutherford, New Jersey (USA), Oct. 15, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) („GlucoTrack“ oder das „Unternehmen“), ein Unternehmen für Medizinprodukte und digitale...
GLUCOTRACK ANNONCE LE RECRUTEMENT DU DR MARK TAPSAK
15. Oktober 2022 09:24 ET
|
GlucoTrack, Inc.
Rutherford, NJ, 15 oct. 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq : GCTK) (« GlucoTrack » ou la « Société »), une société de dispositifs médicaux et de plateformes de santé numériques axée...
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK
14. Oktober 2022 09:45 ET
|
GlucoTrack, Inc.
INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM Rutherford, NJ, Oct. 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a...
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK
14. Oktober 2022 09:30 ET
|
GlucoTrack, Inc.
INDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM Rutherford, NJ, Oct. 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a...
GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEM
10. Oktober 2022 08:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in...
GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor
22. Juni 2022 08:30 ET
|
GlucoTrack, Inc.
Rutherford, NJ and Or Yehuda, Israel, June 22, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for...
GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change
14. März 2022 09:15 ET
|
GlucoTrack, Inc.
To begin trading under the Nasdaq Symbol GCTK Rutherford, NJ and Or Yehuda, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), formerly...